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Albuquerque, New MexicoOBJECTIVES The aim of this study was to determine whether Libman-Sacks endocarditis is a path-
ogenic factor for cerebrovascular disease (CVD) in systemic lupus erythematosus (SLE).
BACKGROUND A cardioembolic pathogenesis of SLE CVD manifested as: 1) neuropsychiatric
systemic lupus erythematosus (NPSLE), including stroke and transient ischemic attacks (TIA); 2) neurocog-
nitive dysfunction; and 3) magnetic resonance imaging of focal brain lesions has not been established.
METHODS A 6-year study of 30 patients with acute NPSLE (27 women, 38  12 years of age), 46 age-
and sex-matched SLE controls without NPSLE (42 women, 36  12 years of age), and 26 age- and
sex-matched healthy controls (22 women, 34  11 years of age) who underwent clinical and laboratory
evaluations, transesophageal echocardiography, carotid duplex ultrasound, transcranial Doppler ultra-
sound, neurocognitive testing, and brain magnetic resonance imaging/magnetic resonance angiography.
Patients with NPSLE were re-evaluated after 4.5 months of therapy. All patients were followed clinically
for a median of 52 months.
RESULTS Libman-Sacks vegetations (87%), cerebromicroembolism (27% with 2.5 times more events
per hour), neurocognitive dysfunction (60%), and cerebral infarcts (47%) were more common in NPSLE
than in SLE (28%, 20%, 33%, and 0%) and healthy controls (8%, 0%, 4%, and 0%, respectively) (all p #
0.009). Patients with vegetations had 3 times more cerebromicroemboli per hour, lower cerebral blood
ﬂow, more strokes/TIA and overall NPSLE events, neurocognitive dysfunction, cerebral infarcts, and brain
lesion load than those without (all p # 0.01). Libman-Sacks vegetations were independent risk factors of
NPSLE (odds ratio [OR]: 13.4; p < 0.001), neurocognitive dysfunction (OR: 8.0; p ¼ 0.01), brain lesions (OR:
5.6; p ¼ 0.004), and all 3 outcomes combined (OR: 7.5; p < 0.001). Follow-up re-evaluations in 18 of 23
(78%) surviving patients with NPSLE demonstrated improvement of vegetations, microembolism, brain
perfusion, neurocognitive dysfunction, and lesion load (all p # 0.04). Finally, patients with vegetations
had reduced event-free survival time to stroke/TIA, cognitive disability, or death (p ¼ 0.007).
CONCLUSIONS The presence of Libman-Sacks endocarditis in patients with SLE was associated
with a higher risk for embolic CVD. This suggests that Libman-Sacks endocarditis may be a source of ce-
rebral emboli. (J Am Coll Cardiol Img 2013;6:973–83) ª 2013 by the American College of Cardiology
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974erebrovascular disease (CVD) in systemic
lupus erythematosus (SLE) is common, is
associated with increased morbidity and
mortality, and manifests as: 1) major
neuropsychiatric systemic lupus erythematosus
(NPSLE) syndromes of stroke, transient ischemic
attacks (TIA), confusional state, or seizures; 2) acute
or cumulative neurocognitive dysfunction; and 3)
focal brain lesions on magnetic resonance imaging
(MRI) (1–5). CVD in SLE is usually attributed to
cerebritis, vasculitis, hypercoagulability, atheroscle-
rosis, or antineuronal antibodies (5–9). However,
CVD in SLE often occurs independently of theseSee page 984conditions (10–12). Libman-Sacks endocarditis
characterized by noninfective inﬂammatory and/or
thrombotic vegetations is also common in SLE andease
e
sus
tack
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This research
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Manuscript ris associated with increased morbidity and
mortality (13). The relationship of
Libman-Sacks endocarditis with CVD in
SLE has not been established because
small, retrospective, or noncontrolled studies
have used transthoracic echocardiography
(TTE), a method with lower sensitivity and
speciﬁcity than transesophageal echocardi-
ography (TEE) for detection of Libman-
Sacks endocarditis (14,15); because of
incomplete clinical or imaging data not
timed to clinical events; and because of in-
clusion of patients with confounding age-
related heart and brain disease. Thus, this6-year, fully integrated, controlled, cross-sectional,
longitudinal study was designed to establish the rela-
tionship betweenLibman-Sacks endocarditis detected
by TEE and cerebroembolism, NPSLE, neuro-
cognitive dysfunction, and focal brain injury.
METHODS
Study populations. The study design and protocol
was approved by the National Institutes of Health
and our institutional review board, and participants
provided informed consent. From December 2006
to December 2012, 76 of 266 patients with SLESchool of Medicine, Albuquerque, New Mexico; #Division of N
, New Mexico; and the **Division of Hematology, University of
was funded by grant RO1-HL04722-01-A6 from the National
y grant 8UL1-TR000041 from the National Center for Resea
relevant to the contents of this paper to disclose.
eceived March 22, 2013; revised manuscript received April 18,(29%) actively followed at the rheumatology clinics of
the University of New Mexico were consecutively
recruited and classiﬁed at enrollment into 2 study
groups.
ACUTE NPSLE GROUP. Thirty patients (27 women,
38  12 years of age) with NPSLE manifesting as
acute stroke/TIA (n ¼ 23), cognitive dysfunction
(n ¼ 11), confusional state (n ¼ 7), or seizures (n ¼
4) were included in the acute NPSLE group. The
occurrence of NPSLE in 30 of 266 screened patients
over a 6-year period constituted cumulative and
annual event rates of 11.3% and 1.9%, respectively,
similar to those reported in inception studies (1).
SLE CONTROL GROUP. Forty-six age- and sex-
matched patients with SLE (42 women, 36  12 years
of age) without clinically manifested acute or past
NPSLE were included in the SLE control group.
Patients were excluded due to age <18 or
>60 years, pregnancy, heart or brain disease unrelated
to SLE, atrial ﬁbrillation or ﬂutter, cardiomyopathy,
intracardiac thrombi, drug abuse, renal dysfunction,
difﬁcult venous access, self-withdrawal or noncom-
pliance with study protocol, or contraindications to
TEE or MRI.
For validation of blinded interpretation and diag-
nostic accuracy of tests and to provide a normality
reference, 26 apparently healthy volunteers age- and
sex-matched to patients were studied. Controls were
recruited by the study coordinator from available
listings of volunteers in the Ofﬁce of Research of the
Health Sciences Center, employees of the University
of New Mexico, and patients’ relatives or acquain-
tances. Candidate volunteers were then screened with
a standard general health questionnaire.
All 102 participants underwent a standardized
protocol of clinical and laboratory evaluations, TEE,
carotid duplex ultrasound, transcranial Doppler ul-
trasound, complete neurocognitive testing, and brain
MRI/magnetic resonance angiography (MRA)
within 1 week of enrollment. All studies were coded,
deidentiﬁed, and interpreted by experienced observers
blinded to participants’ clinical and imaging data.
Clinical and laboratory evaluations. Patients were
characterized with regard to disease duration, ac-
tivity, injury, therapy, and standard autoantibodies
(11,16,17) (Online Table 1). All 102 participantseuroradiology, University of New Mexico School of Medicine,
New Mexico School of Medicine, Albuquerque, New Mexico.
Institutes of Health/National Heart, Lung and Blood Institute
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2013, accepted April 23, 2013.
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975were further characterized for demographics,
atherogenic risk factors, and speciﬁc parameters of
inﬂammation, platelet activity, coagulation, and
ﬁbrinolysis (Online Table 2).
Transesophageal echocardiography. Participants
underwent complete TEE with IE-33 Philips sys-
tems (Philips Healthcare, Andover, Massachusetts)
with images digitally acquired for ofﬂine interpre-
tation. Heart valves were imaged in multiple planes
at a depth of 4 to 8 cm with a narrow sector scan to
improve image resolution.
CRITERIA FOR INTERPRETATION. Libman-Sacks
vegetations were deﬁned as abnormal localized
echodensities with well-deﬁned borders as either part
of or adjacent to valve leaﬂets or subvalvular appa-
ratus (13). Size of vegetations was determined by
planimetry. Valve thickening was determined using
M-mode imaging and was considered present when
thickness >3 mm (mitral valve) or >2 mm (aortic
valve) was observed in $2 leaﬂets or in 1 leaﬂet if
associated with vegetation, at least mild regurgita-
tion, or both (13,18). Mitral or aortic regurgitation
assessed by standard color Doppler criteria was
present if worse than mild or if mild and associated
with a vegetation or thickening of the respective
valve (13,19). In 30 randomly selected TEE studies
(22 patients, 8 controls), interobserver agreement for
detection of valve vegetations, thickening, and
regurgitation were 93%, 83%, and 90%, respectively
(kappa 0.87, 0.67, and 0.73, respectively).
The left atrium and ventricle were assessed for
spontaneous echocardiographic contrast or thrombus;
the atrial septum was interrogated by 2-dimensional,
color Doppler, and saline contrast images for detec-
tion of aneurysms, patent foramenovale, or atrial septal
defects. The ascending aorta, arch, and descending
thoracic aorta were assessed by 2-dimensional and
M-mode images for intima-media thickening ($2SD
above the mean of healthy controls) and plaques (focal
thickening of intima-media exceeding 50% of the
surrounding wall) (20).
Carotid duplex. From longitudinal B-mode images
of both common carotid arteries, 6 measurements
of intima-media thickness along the far and near
walls were performed at end-diastole (21). Carotid
intima-media thickening and plaques were deter-
mined with criteria described for the aorta.
Transcranial Doppler. Both middle cerebral arteries
were interrogated for 90 min for detection of
microemboli using a 2.0-MHz DWL Doppler Box
with power Doppler M-mode, 32-gate spatial im-
aging, and dual-channel emboli detection software.
Microemboli were deﬁned as audible, high-intensity(>13 db), and <100 ms unidirectional signals
within both Doppler blood ﬂow velocity and vessel
lumen (22). Intraobserver agreement for detection
of microemboli was 96% (kappa 0.83).
Neurocognitive evaluation. Participants underwent
complete neurocognitive testing for pre-morbid in-
telligence, attention, memory, language, processing
speed, executive function, motor function, and
global neurocognitive function (23).
Brain MRI/MRA. Standard T1-weighted, ﬂuid-
attenuated inversion recovery, and diffusion-weighted
images were obtained. Dynamic susceptibility con-
trast MRI was performed in 89 participants (64
patients, 25 controls; 92%) to assess brain perfusion
(24). Brain lesions were classiﬁed as old or recent
cerebral infarcts and small focal periventricular or
deep white abnormalities using standard criteria
(3,4,10).Counts of brain lesions and hemispheric and
whole-brain lesion load in cm3 were determined us-
ing semiautomated methods (25). Cerebral athero-
sclerosis, thrombosis, vasculitis, or aneurysms were
determined using MRA (26). Interobserver agree-
ment for detection of brain lesions in 68 studies was
94% (kappa 0.88).
Follow-up. To further assess the relationship of
Libman-Sacks vegetations with cerebroembolism
and CVD, 18 of 23 surviving patients with NPSLE
(78%) underwent re-evaluations after 4.5 months
(interquartile range [IQR]: 2.1 to 8.4 months) of
clinically indicated antimalarial (87%), corticoste-
roid (50%), immunosuppressive (58%), antiplatelet
(71%), or anticoagulant (35%) therapy. Five patients
had no follow-up studies because they were too ill to
undergo TEE or MRI. All 76 patients underwent
clinical follow-up for a median of 52 months (IQR:
24 to 64 months) for development of new or
recurrent stroke/TIA, cognitive disability (deﬁned
as formal physician recommendation for cognitive
disability and a global neurocognitive score $1.5
SD below pre-morbid intelligence score), or death.
Statistical analysis. Descriptive statistics are mean 
SD or median and IQR in asymmetrically distrib-
uted variables or frequencies (%). Comparisons
among the 3 study groups (Table 1) were performed
by analysis of variance for continuous measures and
veriﬁed by Kruskal-Wallis tests. Two-tailed Fisher
exact tests were used for binary measures. Pairwise
comparisons among 3 groups for each variable
were done by Fisher least signiﬁcant differences
method. Association of vegetations with cere-
bromicroembolism and neurological outcomes are
reported in Table 2. The rate ratio (95% conﬁdence
interval [CI]) of microembolism in patients with
NPSLE and SLE and in those with and without
Table 1. Findings on Cardiovascular and Brain Imaging and Neurocognitive Testing
Acute NPSLE
(n [ 30)
SLE
(n [ 46)
Controls
(n [ 26) p Value
Transesophageal echocardiography
Valve vegetations 26 (87)*y 13 (28) 2 (8) <0.001
Mitral valve 20 (67)*y 6 (13) 1 (4) <0.001
Aortic valve 14 (47)*y 11 (24) 2 (8) 0.004
Valve thickening 26 (87)*y 16 (35)* 2 (8) <0.001
Mitral valve 20 (67)*y 8 (17)* 0 <0.001
Aortic valve 18 (60)*y 12 (26) 2 (8) 0.002
Valve regurgitation 15 (50)*y 5 (11) 0 <0.001
Mitral valve 13 (43)*y 4 (9) 0/25 <0.001
Aortic valve 2 (7) 3 (7) 0 0.60
Any valve abnormality 28 (93)*y 18 (39)* 3 (12) <0.001
PFO or interatrial septal aneurysm 1 (3)y 11 (24) 2 (8) 0.03
LV ejection fraction <50% 2 (7) 0 0 0.15
Aorta intima-media thickness 0.88  0.37* 0.80  0.23* 0.66  0.15 0.01
Aorta intima-media thickening 7/29 (24) 10/45 (22) 1 (4) 0.07
Aorta plaque (any portion) 9 (30)* 8 (17)* 0 0.007
Aorta intima-media thickening or plaque 11 (37)* 14 (30)* 1 (4) 0.006
Carotid artery duplex
Intima-media thickness 0.55  0.11*y 0.50  0.07 0.48  0.08 0.01
Intima-media thickening 4 (13) 1 (2.2) 1 (4) 0.11
Plaque 5 (17) 1 (2.2) 2 (8) 0.06
Intima-media thickening or plaque 8 (27)y 2 (4) 3 (12) 0.02
Transcranial Doppler
Right or left MCA microemboli 8 (27)*y
17 events/43.1 h*y
9 (20)
11 events/68.5 h*
0 0.009; HR: 2.5
(p ¼ 0.02)
Neurocognitive z-scores
Clinical domain
Pre-morbid intelligence 0.67  1.17 (27) 0.46  0.93 (45) 0.06  1.03 0.10
Attention 3.14  3.60*y 0.91  0.92 (45) 0.06  0.82 <0.001z
Memory 1.54  1.43 (29)* 1.03  0.90 (45)* 0.056  0.81 <0.001z
Language 1.02  1.04 (27)* 0.99  1.16 (45)* 0.05  0.89 <0.001z
Processing speed 2.19  1.95 (28)*y 0.87  1.15 (45)* 0.06  0.93 <0.001z
Executive function 3.58  3.58 (29)*y 1.63  2.20 (45)*y 0.10  0.79 <0.001z
Motor function 5.17  8.67 (26)*y 1.70  1.66 (37) 0.056  0.63 <0.00z
Global 2.76  2.54*y 1.19  0.91 (45)*y 0.07  0.52 <0.001z
Global abnormalx 18 (60)*y 15 (33)* 1 (4) <0.001z
Brain lesions on MRI
Any focal brain lesion 22 (73)*y 19/45 (42)*k 4 (15)k <0.001
Focal brain lesions, n 12 (3, 47)* 2 (0, 9) 0 (0, 2) <0.001{
Old or recent cerebral infarcts 14 (47)*y 0 0 <0.001
Cerebral infarcts, n 0 (0, 2)*y 0 0 <0.001{
White matter abnormalities 20 (67)*y 18/45 (40)* 4 (15) <0.001
White matter abnormalities, n 9 (1, 46)*y 2 (0, 9) 0 (0, 2) <0.001{
White matter brain lesion load, cm3
Left hemisphere 0.96 (0.16, 2.21)*y 0.13 (0.05, 0.23) 0.04 (0.03, 0.15) 0.003{
Right hemisphere 1.23 (0.18, 2.84)* 0.11 (0.05, 0.24) 0.05 (0.03, 0.10) 0.01{
Whole brain 2.92 (3.18, 5.55)*y 0.26 (0.13, 0.38) 0.13 (0.07, 0.23) 0.002{
Values are n (%), mean  SD (range), or median (IQR). *p < 0.05 compared with controls by Fisher post hoc least signiﬁcant differences method. yp < 0.05 for acute
neuropsychiatric systemic lupus erythematosus (NPSLE) compared with SLE by Fisher post hoc least signiﬁcant differences method. zAll p# 0.009 after simultaneously
adjusting for education, pre-morbid intelligence, and depression index. xGlobal abnormal deﬁned as $1.5 standard deviations (SD) below the mean total of controls.
kOne SLE patient did not complete magnetic resonance imaging (MRI) studies due to claustrophobia; includes 2 controls with history of sports-related head trauma.
{By Kruskal-Wallis test.
HR ¼ hazard ratio; IQR ¼ interquartile range; LV ¼ left ventricle; MCA ¼ middle cerebral artery; PFO ¼ patent foramen ovale.
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Table 2. Association of Libman-Sacks Vegetations With Microembolism,
Acute Stroke/TIA and Overall NPSLE, Neurocognitive Dysfunction, and Brain
Lesions and Lesion Load
Patients With
Vegetations
(n [ 39)
Patients Without
Vegetations
(n [ 37) p Value
Microembolism
Right or left MCA
microemboli
12 (31)
21 events/56.6 h
5 (14)
7 events/55 h
Adjusted HR*: 3.0;
p ¼ 0.01
NPSLE
Acute stroke/TIA 22 (56) 1 (3) <0.001
Acute overall NPSLE 26 (67) 4 (11) <0.001
Neurocognitive z-scores
Attention 2.36  3.00 0.82  0.91 0.02y
Memory 1.75  1.27 0.79  1.00 0.001y
Processing speed 1.90  1.92 0.90  1.15 0.04y
Executive function 3.31  3.60 1.68  2.53 0.03y
Motor function 4.38  7.40 1.40  1.54 0.005y
Global 2.42  2.32 1.17  0.98 0.01z
Focal brain lesions
Focal brain lesions 28 (72) 12/36 (34)x <0.001
Focal brain lesions, n 9 (3, 39) 1 (0, 8) 0.004y
Cerebral infarcts 14 (36) 0/36 <0.001
Cerebral infarcts, n 0 (0, 2) 0 <0.001y
White matter lesions 25/37 (68) 12/36 (34) 0.005
White matter lesions, n 8 (1, 37) 1 (0, 8) 0.004y
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977vegetations was estimated by Poisson regression
with individual observation time as the offset. Neu-
rocognitive z-scores were computed using controls as
reference. Differences in cerebral blood ﬂow in gray
and white matter of 4 cerebral lobes and 2 hemi-
spheres due to vegetations and microembolism were
analyzed by repeated-measures analysis of variance.
Using clinical, laboratory, and cardiovascular imag-
ing measures listed in Table 1 and Online Tables 1
and 2, signiﬁcant risk factors in univariate logistic
regression for NPSLE, neurocognitive dysfunction,
brain lesions, and all 3 outcomes combined were
considered candidate risk factors in multivariate
logistic regression analyses (Table 3). The list of
candidate risk factors is detailed in Online Table 3.
Effects are reported as adjusted odds ratios (ORs)
and 95% CI with Firth bias correction in near-
separation conditions. The effect of therapy in
follow-upwas assessed byWilcoxon signed-rank test
as a robust, nonparametric paired comparison
(Table 4). Kaplan-Meier event-free survival curves
for stroke/TIA, cognitive disability, or death related
to vegetations were compared by log-rank tests. A
Cox proportional hazards model was used to select
predictors of this combined event. Two-tailed p
values #0.05 were considered signiﬁcant. All sta-
tistical analyses were performed in SAS version 9.3
(SAS Institute, Inc., Cary, North Carolina).Brain lesion load, cm
Left hemisphere 0.05 (0, 1.23) 0 (0, 0.09) 0.016y
Right hemisphere 0.14 (0, 1.15) 0.01 (0, 0.06) 0.002y
Whole brain 0.18 (0, 2.34) 0.026 (0, 0.16) 0.008y
Values are n (%), mean  SD, or median (IQR). *Poisson regression with repeated measures adjusting for
PFO, interatrial septal aneurysm, carotid or aortic atherosclerosis, and antiphospholipid antibodies.
yWilcoxon test. zp ¼ 0.02 after simultaneously adjusting for age, depression index, pre-morbid intelligence,
and education. xOne of the patients without vegetations had no MRI due to claustrophobia.
TIA ¼ transient ischemic attack; other abbreviations as in Table 1.RESULTS
Clinical characteristics. Patients with NPSLE as
compared with SLE were more often treated with
statins and aspirin or warfarin, were more
commonly positive for SSA and b2-glycoprotein
antibodies, had higher triglyceride levels, had
lower hemoglobin and serum albumin levels, and
had higher levels of D-dimer and tissue plasmin-
ogen antigen (all p# 0.04) (Online Tables 1 and 2).
Patients with NPSLE and SLE differed from
controls in multiple clinical and laboratory
parameters.
Findings on cardiovascular imaging, neurocognitive
testing, and brain MRI. Patients with NPSLE as
compared with SLE and healthy controls had more
Libman-Sacks vegetations, valve thickening, valve
regurgitation, any valve abnormality, mild carotid
atherosclerosis, cerebral microembolism (Poisson
regression, 2.5 times more events per hour; 95% CI:
1.2 to 5.3; p ¼ 0.02), neurocognitive dysfunction,
and brain lesions and lesion load (all p # 0.02)
(Table 1). Patent foramen ovale and interatrialseptal aneurysms were more common in patients
with SLE than in patients with NPSLE (p ¼ 0.03).
Vegetations were of oval shape, heterogeneous
or soft tissue echoreﬂectance, sessile, and of vari-
able maximal diameter (5.8  2.7 mm; range 2.8 to
14 mm) and area (0.37  0.36 cm2; range 0.04 to
1.51 cm2); were seen on the atrial side and tips of
mitral leaﬂets and on the ventricular or aortic side
of aortic cusps; and were highly associated with
valve thickening (81% to 92%; p < 0.001) (Online
Videos 1, 1A, 2A, 2B, 2E, 2F, 3A, 3D, 3F, 4A,
5A, 5D, 5E, and 5F).
Cerebromicroembolism was similarly frequent
in the right and left middle cerebral arteries.
Consequently, focal brain lesions always involved
both hemispheres (Fig. 1, Online Figs. 1 to 5).
Table 3. Independent Risk Factors of Acute NPSLE, Neurocognitive Dysfunction,
Brain Lesions on MRI, and All 3 Outcomes Combined
Odds Ratios (95% CI) p Value*
Acute NPSLE
Valve vegetations 13.40 (3.31–54.35) <0.001
Valve regurgitation 5.10 (1.19–21.93) 0.03
Triglyceride levels (per 20 mg/dl) 1.27 (1.04–1.53) 0.02
Global neurocognitive dysfunction
Vegetations and microembolism 8.01 (1.51–42.62) 0.01
Smoking (currently) 3.79 (1.16–12.40) 0.03
Non-neurological SLICC damage index 1.50 (1.06–2.13) 0.02
Age at diagnosis of SLE (per 10 years) 2.08 (1.27–3.40) 0.004
Focal brain lesions
Valve vegetations 5.57 (1.72–18.01) 0.004
P-selectin 1.04 (1.00–1.07) 0.02
Complement C4 1.12 (1.03–1.22) 0.009
Acute NPSLE, cognitive dysfunction,
or brain lesions
Valve vegetations 7.49 (2.49–22.5) <0.001y
Triglyceride levels (per 20 mg/dl) 1.28 (1.03–1.60) 0.03
P-selectin 1.05 (1.01–1.09) 0.02
Complement C4 1.17 (1.04–1.32) 0.008
*p values for multivariate analysis adjusted for other variables in the “best” stepwise model. yOR and p
value adjusted in “best” stepwise model of predictors selected from all 3 components/outcomes as listed
above.
SLICC ¼ Systemic Lupus International Collaborative Clinics; other abbreviations as in Table 1.
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978Association of Libman-Sacks vegetations with cerebro-
microembolism and CVD. As noted in Table 1,
patients without NPSLE (SLE group) commonly
had vegetations (28%), cerebromicroemboli (20%),
cognitive dysfunction (33%), and brain lesions
(42%), suggestive of subclinical cerebroembolism.
Therefore, for better deﬁnition of the association of
vegetations with cerebromicroembolism, NPSLE,
cognitive dysfunction, and brain injury, all patients
with SLE were stratiﬁed into those with and
without vegetations. As shown in Table 2, 39 pa-
tients with vegetations compared with 37 without
vegetations had 3 times more cerebromicroembolic
events per hour after simultaneously adjusting for
patent foramen ovale, interatrial septal aneurysm,
carotid or aortic atherosclerosis, and anti-
phospholipid antibodies (95%CI: 1.3 to 7.2; p¼ 0.01),
more stroke/TIA and overall NPSLE events, lower
neurocognitive scores, and more brain lesions and
lesion load (all p # 0.04). Also, 12 patients with
vegetations and microemboli as compared with 32
patients with neither had lower cerebral blood ﬂow
(Fig. 2), more stroke/TIA and NPSLE events,
lower neurocognitive scores, and more cerebralinfarcts and lesion load (all p # 0.03) (Online
Table 4).
Independent risk factors for CVD. Libman-Sacks
vegetations (OR: 13.4; p < 0.001), valve regurgi-
tation, and triglyceride levels were independent
risk factors for NPSLE; vegetations and cere-
bromicroemboli (OR: 8.0; p ¼ 0.01), current
smoking, non-neurological damage index, and age at
diagnosis of SLE were risk factors for neurocognitive
dysfunction; vegetations (OR: 5.6; p ¼ 0.004) and
P-selectin and complement C4 levels were risk fac-
tors for focal brain lesions; and vegetations (OR: 7.5;
p< 0.001), triglyceride levels, and P-selectin and C4
levels were risk factors for all 3 outcomes combined
(Table 3).
Follow-up ﬁndings. In support of the relationship of
Libman-Sacks vegetations with cerebroembolism
and CVD, re-evaluations in 18 of 23 survivors
(78%) of treated NPSLE demonstrated improve-
ment of vegetations, cerebromicroembolism, cere-
bral blood ﬂow, neurocognitive function, and brain
lesion load (all p # 0.04) (Table 4, Online Figs. 1
to 5). During follow-up, 19 of 76 patients (25%)
developed major clinical events. Twelve patients
(16%) developed new or recurrent stroke/TIA (9 of
12 patients underwent re-evaluations, and all had
recurrent or persistent vegetations [n ¼ 8], cere-
bromicroemboli [n ¼ 5], or brain lesions [n ¼ 9])
(Online Figs. 1 to 5), 10 (14%) developed cognitive
disability, and 7 (9%) died. Fifteen of 39 patients
with vegetations (38%) developed events as com-
pared with 4 of 37 without vegetations (11%;
p ¼ 0.008). Kaplan-Meier analysis demonstrated
reduced event-free survival in patients with vege-
tations (time to death p ¼ 0.06; time to disability
p ¼ 0.04; time to stroke/TIA p ¼ 0.003; time to
combined event p ¼ 0.007) (Fig. 3). Vegetations,
aortic or carotid atherosclerosis, and P-selectin
levels were independent predictors of the combined
event by Cox proportional hazards stepwise analysis
(hazard ratio: 4.8, 4.1, and 1.4, respectively; all
p # 0.008).DISCUSS ION
This 6-year, fully integrated, controlled, cross-
sectional, longitudinal study revealed 5 major ﬁnd-
ings: 1) patients with NPSLE as compared with
SLE had more Libman-Sacks vegetations, cere-
bromicroemboli, neurocognitive dysfunction, and
focal brain lesions; 2) patients with vegetations had
3.0 times more cerebromicroemboli per hour, lower
cerebral perfusion, more stroke/TIA and overall
Table 4. Findings on Initial and Follow-up Cardiovascular and Brain Imaging and
Neurocognitive Testing in 18 Patients With Treated NPSLE
Finding Initial Study
Follow-up
Study p Value*
Transesophageal echocardiography
Vegetations, n 2.0  1.41 1.33  1.28 0.03
Vegetations, area, cm2 0.38  0.46 0.18  0.19 0.09
Transcranial Doppler
Right or left MCA microemboli 5 patients (28%)
with 14 microemboli
0 0.007y
Neurocognitive z-scores
Attention 3.55  4.24 2.26  3.20 0.002
Memory 1.62  1.64 0.88  1.61 0.001
Motor function 6.43  10.46 2.32  2.70 0.002
Processing speed 2.17  2.01 1.73  2.41 0.02
Global cognitive dysfunction 3.12  3.08 1.86  2.32 <0.001
Brain perfusion, ml/min/100 g of tissue, (n ¼ 11) D%/p value*
Overall gray matter 28.10  18.04 33.87  15.02 34%/0.02
Overall white matter 14.36  9.73 17.47  6.88 38%/0.02
Frontal lobe (gray matter) 26.45  17.58 32.19  14.62 36%/0.02
Frontal lobe (white matter) 12.76  9.14 15.60  6.53 40%/0.01
Parietal lobe (gray matter) 29.25  19.16 35.78  15.20 38%/0.02
Parietal lobe (white matter) 13.87  9.02 17.21  6.19 41%/0.02
Temporal lobe (gray matter) 28.23  16.97 33.78  15.21 31%/0.04
Temporal lobe (white matter) 14.70  10.31 17.85  7.68 38%/0.02
Occipital lobe (gray matter) 28.46  18.62 33.73  15.39 32%/0.03
Occipital lobe (white matter) 16.10  10.56 19.21  7.27 35%/0.02
Brain lesion load
Whole brain lesion load, cm3 0.68 (0.17, 3.93) 0.55 (0.07, 1.74) 0.03
Values are mean  SD, n (%), or median (IQR). *Wilcoxon signed-rank test. yPoisson regression with
repeated measures.
Abbreviations as in Table 1.
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979NPSLE events, greater neurocognitive dysfunction,
and greater brain injury; 3) valve vegetations were
strong independent risk factors for stroke/TIA
and NPSLE, neurocognitive dysfunction, brain le-
sions, and all 3 outcomes combined; 4) vegetations,
cerebromicroembolism, NPSLE, neurocognitive
dysfunction, and brain perfusion and lesion load
improved with anti-inﬂammatory and/or antith-
rombotic therapy; and 5) patients with vegetations
had poor outcomes, with reduced event-free time to
stroke/TIA, cognitive disability, or death. These
ﬁndings support that Libman-Sacks vegetations
may generate platelet or ﬁbrin macroemboli or
microemboli that occlude cerebral vessels and result
in reduced cerebral perfusion, ischemic brain injury,
stroke/TIA, nonfocal NPSLE syndromes, neuro-
cognitive dysfunction or disability and contribute to
death. Thus, Libman-Sacks endocarditis may be a
common and under-recognized pathogenesis of
embolic CVD in SLE.
Age at diagnosis of SLE, non-neurological
damage index, triglyceride levels, smoking, P-selectin
(a cell adhesion molecule indicative of platelet activa-
tion and aggregation and endothelial cell activation or
injury) levels (27), and complement C4 levels were
also independent risk factors of CVD. Thus, disease
duration and severity, atherogenic risk factors,
platelet aggregation, and endothelial inﬂammation
may be risk factors for valve vegetations, endothelial
dysfunction, early atherosclerosis, and thrombosis
and thus either contribute to thromboembolic CVD
or are independent risk factors for CVD (28).
Previous, often retrospective, noncontrolled, or
nonintegrated clinical and pathological studies
support our ﬁndings. In a TTE study of 105 pa-
tients, unspeciﬁed valve disease was detected in 7 of
18 patients (39%) with past stroke (29). In our 1996
controlled study of 69 patients undergoing serial
TEE, Libman-Sacks endocarditis detected in 61%
of patients was associated with 11% incidence of
stroke/TIA and a mortality of 12% during a 5-year
follow-up (13). In another TTE study, any valve
abnormality detected in 44% of 71 patients was
associated with past stroke/TIA (30). In 3 retro-
spective studies from our institution (2 using TEE),
valve vegetations were associated with past stroke/
TIA, nonfocal NPSLE, and brain lesions on MRI
(31–33). In a prospective noncontrolled TTE study,
Libman-Sacks vegetations detected in 11% of 342
patients with SLE were associated with a higher
incidence of stroke/TIA (14.8% in those with vs.
3% in those without vegetations) during a 4-year
follow-up (34). With transcranial Doppler in
70 patients, 39% of 38 patients with versus noneof 32 without antiphospholipid antibodies had
microembolism associated with cerebrovascular
ischemia and mitral valve prolapse (35). In another
study (n ¼ 53), patients with versus those without
NPSLE had 5.4  1.1 versus 0.3  0.8 micro-
emboli per hour, respectively (36). Microembolism
in 9% of 55 patients in one study and in 15% of 109
patients in another study was associated with cere-
bral infarcts and/or cognitive dysfunction (37,38).
Microembolism in 10.3% of 68 patients was more
common in those with than without NPSLE (25%
vs. 2.2%, respectively) (39). In these transcranial
Doppler studies, valve disease was not assessed, but
cerebromicroembolism was not associated with
atherogenic risk factors or carotid atherosclerosis
and was associated with antiphospholipid antibodies
only in one study. In a post-mortem study of 50
patients, 9 of 10 patients with cerebral infarcts had
Figure 1. 55-Year-Old Woman With SLE and Acute Transient Ischemic Attack
(A) This transesophageal echocardiography view demonstrates a moderately sized, elongated, sessile, and heterogeneously echoreﬂectant Libman-Sacks vegetation
(arrow) on the atrial side of the posterior mitral leaﬂet (pml) (Online Video 1). Moderate thickening and sclerosis with decreased mobility of the mid and distal portions
of the anterior mitral leaﬂet (aml) and pml are noted. (B) Transcranial Doppler ultrasound demonstrates a microembolic signal on the spectral Doppler (upper arrow)
and vessels lumen (lower arrow) traveling through the left middle cerebral artery (red power M-mode) and anterior communicating artery (blue power M-mode).
(C and D) Brain magnetic resonance imaging demonstrates multiple, bilateral, and variably sized periventricular and deep white matter infarcts (arrows). This patient
had 75 brain lesions and a lesion load of 6.04 cm3. Her global neurocognitive z-score was 4.28, indicative of severe neurocognitive dysfunction. (E) Histopathology
with hematoxylin and eosin (H&E 40) stains demonstrates thickening and ﬁbrosis of the posterior leaﬂet with a well-adhered, verrucoid, ﬁbrinous vegetation (arrow).
(F) (H&E 20) Subacute cerebral infarct at the junction of the white and gray matter with necrotic debris and moderate cellular inﬁltration (arrow). (G and H) (H&E
40 and 100, respectively) Old deeper (white matter) infarct with liquefactive necrosis, residual macrophages, and gliosis (arrows). (I) (H&E 100) Large cerebral
vessel with ﬁbrin thrombi (arrow). (J) (H&E 100) Small cerebral vessel with ﬁbrin thrombi and neoangiogenesis (arrows). Multiple subacute and old microinfarcts and
ﬁbrin thrombosed microvasculature with neoangiogenesis characteristic of chronic cardiothromboembolic disease were demonstrated in both cerebral hemispheres.
Please also see Online Videos 1A, 2A, 2B, 2E, 2F, 3A, 3D, 3F, 4A, 5A, 5D, 5E, and 5F. LA ¼ left atrium; LV ¼ left ventricle; SLE ¼ systemic lupus erythematosus.
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Figure 2. Cerebral Blood Flow in Patients With SLE With Vegetations and
Cerebromicroembolism
Cerebral blood ﬂow (ml/min/100 g of tissue) in the gray andwhitematter is signiﬁcantly lower
in 11 patients with vegetations and cerebromicroemboli as compared with that in 24 patients
with neither across the 4 cerebral lobes and left and right hemispheres (repeated-measures
analysis of variance p # 0.001 for both gray and white matter). Gray & no veg/MES ¼ gray
matter perfusion in patients with no vegetations and no cerebromicroembolism; gray &
veg/MES ¼ gray matter perfusion in patients with vegetations and cerebromicroembolism;
white & no veg/MES ¼ white matter perfusion in patients with no vegetations and no
cerebromicroembolism; white & veg/MES ¼ white matter perfusion in patients with
vegetations and cerebromicroembolism; other abbreviations as in Figure 1.
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Figure 3. Kaplan-Meier Event-Free Survival in Patients With SLE With and
Without Vegetations
During follow-up, the event-free survival from stroke/transient ischemic attack, cognitive
disability, or death of patients with vegetations (Vegþ) was signiﬁcantly lower than in those
without vegetations (Veg) (p ¼ 0.007). Abbreviations as in Figure 1.
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981Libman-Sacks endocarditis, chronic valvulitis, or
left heart thrombus (40). In 57 fatal NPSLE cases,
50% had multiple cerebral infarcts with ﬁbrin or
platelet thromboemboli (41). In a study of 14 pa-
tients, focal white matter lesions and cerebral in-
farcts on pre-mortem MRI correlated highly with
old and acute cerebral infarcts and micro-
thromboemboli on histopathology (10). Eight of
these 14 patients (57%) had Libman-Sacks endo-
carditis. In these pathological studies, vasculitis,
cerebritis, and atherosclerosis were rare. In contrast
to prior studies, the present study is the largest and
ﬁrst fully integrated study linking Libman-Sacks
vegetations with cerebromicroembolism, cerebral
hypoperfusion, ischemic brain injury, stroke/TIA,
overall NPSLE, neurocognitive dysfunction, and
death. Improvement with current therapy of
Libman-Sacks vegetations, cerebromicroembolism,
brain perfusion and injury, and neurocognitive
dysfunction further support a causal association of
Libman-Sacks endocarditis and CVD.
The present study has potential limitations. The
difﬁculty of testing patients at onset of CVD and
before therapy; transcranial Doppler sampling for
only 90 min; and exclusion of patients with renal
dysfunction, and thus more aggressive disease, may
have reduced the strength of the association of
vegetations with cerebromicroembolism and CVD.
The study in a tertiary care center may have over-
estimated the association of vegetations with CVD.
However, patients were selected for acute CVD and
not for valve vegetations; thus, a true association
between vegetations and CVD is likely. A hypo-
thetical study design in which “exposure” (vegeta-
tions) precedes the “outcome” (CVD) may be limited
in determining causality due to common resolution
of valve vegetations over time (13) and multiplicity of
potential pathogenesis of CVD. Therefore, such a
design would require re-evaluations during acute
CVD, as in our study design. Cerebroembolism
from Libman-Sacks vegetations leading to break-
down of the blood-brain barrier may be an important
route of entry of antineuronal antibodies into the
brain and should be investigated in future studies.
Detection of focal nodularities or vegetation-like
abnormalities in 2 apparently healthy controls was
conﬁrmed by a second independent observer, and it
is known that apparently healthy populations may
have a 9% to 15% prevalence of silent valve disease
(13,14,42). However, we cannot exclude that such
vegetation-like structures may have been mistaken
with normal variant mimickers of valve masses such
as atypical lamellar type of Lambl excrescences or less
likely nodes of Aranti.This study has several clinical implications.
Libman-Sacks endocarditis is a strong independent
risk factor for CVD in SLE. An increased aware-
ness of this association should lead to a greater focus
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982on the cardiovascular evaluation of patients with
SLE and CVD including use of TEE for increased
detection of vegetations. Because of the semi-
invasive nature of TEE, patients with SLE should
be carefully selected for undergoing such a proce-
dure with the highest diagnostic yield. Our study
results support that it is appropriate to perform
TEE in patients with SLE with: 1) acute, recent
(within 2 to 4 weeks), or recurrent stroke or TIA; or
2) acute, recent (within 2 to 4 weeks), or recurrent
nonfocal neurological manifestations of confusional
state, cognitive dysfunction, or seizures, if they also
have focal brain abnormalities on MRI or cere-
bromicroembolism on transcranial Doppler. Clinical
ﬁndings integrated with those of TEE, transcranial
Doppler, and brain MRI should lead to a prompt
and accurate diagnosis and treatment of Libman-
Sacks endocarditis and CVD, which may prevent
recurrence or progression of CVD.
CONCLUS IONS
The identiﬁcation of valve disease in SLE as a po-
tential source of embolism resulting in ischemic
CVD may also apply to other conditions commonly
associated with valve and brain disease such asrheumatoid arthritis, primary antiphospholipid
syndrome, rheumatic fever, and Behcet disease
(42–46). Current nonstandardized pharmaco-
therapy seems beneﬁcial for Libman-Sacks endo-
carditis and CVD. However, there is a need for a
randomized controlled study to determine the most
appropriate pharmacotherapy (antiplatelet, anti-
coagulation, immunosuppressive, neuroprotective,
lipid-lowering, or combined therapy) for primary
and secondary prevention of potentially disabling
and life-threatening Libman-Sacks endocarditis and
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